HC Wainwright & Co. Maintains Buy on Rigel Pharmaceuticals, Adjusts Price Target To $57 (1-20 Reverse Stock Split)
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Rigel Pharmaceuticals (NASDAQ:RIGL) and adjusted the price target to $57 from $15, reflecting a 1-20 reverse stock split.
August 09, 2024 | 9:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on Rigel Pharmaceuticals and adjusted the price target to $57 from $15, reflecting a 1-20 reverse stock split.
The maintenance of a Buy rating and the significant adjustment in the price target to $57 from $15, reflecting a 1-20 reverse stock split, is likely to positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100